Related Experiment Video
Updated: May 11, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Long-Term Treatment with Erlotinib for EGFR Wild-Type Non-Small Cell Lung Cancer: A Case Report
Genovefa Polychronidou1, Pavlos Papakotoulas
1Theagenio Cancer Hospital, Thessaloniki, Greece.
Abstract:
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung cancer (NSCLC), although erlotinib also has activity in wild-type disease. We report the successful long-term maintenance treatment of a patient with EGFR wild-type NSCLC with gefitinib and later erlotinib. The patient (male; 44 years old; smoker) was diagnosed with EGFR wild-type NSCLC after computer tomography had revealed a mediastinal mass, and histology and mutation testing had identified the tumor as an EGFR wild-type grade 3 adenocarcinoma. The patient received multiple rounds of chemotherapy, followed by gefitinib maintenance (3 years). Later on, he received erlotinib maintenance and developed a persistent rash (grade 1/2) that lasted throughout the treatment. The patient's condition has remained stable on erlotinib for more than 5 years, with no evidence of progression. We describe the patient's disease course and treatment in the context of EGFR TKI therapy and the prognostic factors for long-term clinical outcomes of NSCLC, including the development of erlotinib-induced rash.
Insights
This case study shows long-term maintenance therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) can be effective for non-small cell lung cancer (NSCLC) even in patients with wild-type EGFR. The patient remained stable for over 5 years on erlotinib, despite developing a rash.
Area of Science:
- Oncology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib are standard treatments for non-small cell lung cancer (NSCLC).
- These TKIs demonstrate higher efficacy in patients with EGFR mutations, but erlotinib also shows activity in wild-type EGFR disease.
Observation:
- A 44-year-old male smoker with EGFR wild-type NSCLC received chemotherapy followed by maintenance therapy.
- The patient was treated with gefitinib for 3 years, then transitioned to erlotinib maintenance therapy.
- He developed a persistent grade 1/2 rash during erlotinib treatment, which did not impede treatment continuation.
Findings:
- The patient achieved long-term disease stability on erlotinib maintenance for over 5 years with no evidence of progression.
- This case highlights the potential for long-term efficacy of EGFR TKIs in a subset of EGFR wild-type NSCLC patients.
Implications:
- Long-term maintenance therapy with EGFR TKIs may be a viable option for select patients with EGFR wild-type NSCLC.
- Understanding prognostic factors and managing side effects, such as erlotinib-induced rash, are crucial for successful long-term treatment outcomes in NSCLC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
02:38Mitogens and the Cell Cycle